1. Home
  2. PULM vs OSRH Comparison

PULM vs OSRH Comparison

Compare PULM & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulmatrix Inc.

PULM

Pulmatrix Inc.

HOLD

Current Price

$4.43

Market Cap

14.9M

Sector

Health Care

ML Signal

HOLD

Logo OSR Holdings Inc.

OSRH

OSR Holdings Inc.

HOLD

Current Price

$0.58

Market Cap

12.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PULM
OSRH
Founded
2003
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9M
12.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PULM
OSRH
Price
$4.43
$0.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
9.5K
10.2M
Earning Date
10-16-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$134.88
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.90
$0.45
52 Week High
$10.40
$12.54

Technical Indicators

Market Signals
Indicator
PULM
OSRH
Relative Strength Index (RSI) 49.50 44.48
Support Level $3.95 $0.63
Resistance Level $4.48 $0.77
Average True Range (ATR) 0.32 0.09
MACD 0.01 -0.01
Stochastic Oscillator 50.96 0.00

Price Performance

Historical Comparison
PULM
OSRH

About PULM Pulmatrix Inc.

Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

About OSRH OSR Holdings Inc.

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.

Share on Social Networks: